These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 19344437)

  • 1. A multicenter study of valganciclovir prophylaxis up to day 120 in CMV-seropositive lung transplant recipients.
    Monforte V; Lopez C; Santos F; Zurbano F; de la Torre M; Sole A; Gavalda J; Ussetti P; Lama R; Cifrian J; Borro JM; Pastor A; Len O; Bravo C; Roman A
    Am J Transplant; 2009 May; 9(5):1134-41. PubMed ID: 19344437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: 1-year results of a randomized clinical trial.
    Witzke O; Hauser IA; Bartels M; Wolf G; Wolters H; Nitschke M;
    Transplantation; 2012 Jan; 93(1):61-8. PubMed ID: 22094954
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lower incidence of CMV infection and acute rejections with valganciclovir prophylaxis in lung transplant recipients.
    Johansson I; Mårtensson G; Nyström U; Nasic S; Andersson R
    BMC Infect Dis; 2013 Dec; 13():582. PubMed ID: 24325216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence, risk factors, and outcome of cytomegalovirus infection and disease in patients receiving prophylaxis with oral valganciclovir or intravenous ganciclovir after umbilical cord blood transplantation.
    Montesinos P; Sanz J; Cantero S; Lorenzo I; Martín G; Saavedra S; Palau J; Romero M; Montava A; Senent L; Martínez J; Jarque I; Salavert M; Córdoba J; Gómez L; Weiss S; Moscardó F; de la Rubia J; Larrea L; Sanz MA; Sanz GF
    Biol Blood Marrow Transplant; 2009 Jun; 15(6):730-40. PubMed ID: 19450758
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytomegalovirus Immunoglobulin for Prophylaxis and Treatment of Cytomegalovirus Infection in the (Val)Ganciclovir Era: A Single-Center Experience.
    Lopez Garcia-Gallo C; García Fadul C; Laporta R; Portero F; Millan I; Ussetti P
    Ann Transplant; 2015 Nov; 20():661-6. PubMed ID: 26537426
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk factors, survival, and impact of prophylaxis length in cytomegalovirus-seropositive lung transplant recipients: A prospective, observational, multicenter study.
    Monforte V; Sintes H; López-Gallo C; Delgado M; Santos F; Zurbano F; Solé A; Gavaldá J; Borro JM; Redel-Montero J; Cifrian JM; Pastor A; Román A; Ussetti P
    Transpl Infect Dis; 2017 Jun; 19(3):. PubMed ID: 28294487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of oral valganciclovir prophylaxis for cytomegalovirus infection in heart transplant patients.
    Doesch AO; Repp J; Hofmann N; Erbel C; Frankenstein L; Gleissner CA; Schmidt C; Ruhparwar A; Zugck C; Schnitzler P; Ehlermann P; Dengler TJ; Katus HA
    Drug Des Devel Ther; 2012; 6():289-95. PubMed ID: 23091373
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retrospective review of the incidence of cytomegalovirus infection and disease after liver transplantation in pediatric patients: comparison of prophylactic oral ganciclovir and oral valganciclovir.
    Bedel AN; Hemmelgarn TS; Kohli R
    Liver Transpl; 2012 Mar; 18(3):347-54. PubMed ID: 22139888
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased incidence of cytomegalovirus infection in high-risk liver transplant recipients receiving valganciclovir prophylaxis versus ganciclovir prophylaxis.
    Shiley KT; Gasink LB; Barton TD; Pfeiffenberger P; Olthoff KM; Blumberg EA
    Liver Transpl; 2009 Aug; 15(8):963-7. PubMed ID: 19642123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extended valganciclovir prophylaxis to prevent cytomegalovirus after lung transplantation: a randomized, controlled trial.
    Palmer SM; Limaye AP; Banks M; Gallup D; Chapman J; Lawrence EC; Dunitz J; Milstone A; Reynolds J; Yung GL; Chan KM; Aris R; Garrity E; Valentine V; McCall J; Chow SC; Davis RD; Avery R
    Ann Intern Med; 2010 Jun; 152(12):761-9. PubMed ID: 20547904
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytomegalovirus disease and infection in lung transplant recipients in the setting of planned indefinite valganciclovir prophylaxis.
    Wiita AP; Roubinian N; Khan Y; Chin-Hong PV; Singer JP; Golden JA; Miller S
    Transpl Infect Dis; 2012 Jun; 14(3):248-58. PubMed ID: 22385394
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extending cytomegalovirus prophylaxis in high-risk (D+/R-) lung transplant recipients from 6 to 9 months reduces cytomegalovirus disease: A retrospective study.
    Herrera S; Khan B; Singer LG; Binnie M; Chaparro C; Chow CW; Martinu T; Tomlinson G; Keshavjee S; Husain S; Tikkanen JM
    Transpl Infect Dis; 2020 Aug; 22(4):e13277. PubMed ID: 32170813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytomegalovirus disease among donor-positive/recipient-negative lung transplant recipients in the era of valganciclovir prophylaxis.
    Mitsani D; Nguyen MH; Kwak EJ; Silveira FP; Vadnerkar A; Pilewski J; Crespo M; Toyoda Y; Bermudez C; Clancy CJ
    J Heart Lung Transplant; 2010 Sep; 29(9):1014-20. PubMed ID: 20598582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients.
    Paya C; Humar A; Dominguez E; Washburn K; Blumberg E; Alexander B; Freeman R; Heaton N; Pescovitz MD;
    Am J Transplant; 2004 Apr; 4(4):611-20. PubMed ID: 15023154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of low-dose valganciclovir for prevention of cytomegalovirus disease in renal transplant recipients: a single-center, retrospective analysis.
    Gabardi S; Magee CC; Baroletti SA; Powelson JA; Cina JL; Chandraker AK
    Pharmacotherapy; 2004 Oct; 24(10):1323-30. PubMed ID: 15628830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Valganciclovir for cytomegalovirus prevention in solid organ transplant patients: an evidence-based reassessment of safety and efficacy.
    Kalil AC; Freifeld AG; Lyden ER; Stoner JA
    PLoS One; 2009; 4(5):e5512. PubMed ID: 19436751
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polyfunctional cytomegalovirus-specific immunity in lung transplant recipients receiving valganciclovir prophylaxis.
    Snyder LD; Medinas R; Chan C; Sparks S; Davis WA; Palmer SM; Weinhold KJ
    Am J Transplant; 2011 Mar; 11(3):553-60. PubMed ID: 21219584
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective long-term study on primary CMV infections in adult liver transplant (D+/R-) patients after valganciclovir prophylaxis.
    Lautenschlager I; Loginov R; Mäkisalo H; Höckerstedt K
    J Clin Virol; 2015 Oct; 71():73-5. PubMed ID: 26318605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytomegalovirus prevention in high-risk lung transplant recipients: comparison of 3- vs 12-month valganciclovir therapy.
    Jaksch P; Zweytick B; Kerschner H; Hoda AM; Keplinger M; Lang G; Aigner C; Klepetko W
    J Heart Lung Transplant; 2009 Jul; 28(7):670-5. PubMed ID: 19560694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of Low- Versus High-dose Valganciclovir for Prevention of Cytomegalovirus Disease in High-risk Renal Transplant Recipients.
    Gabardi S; Asipenko N; Fleming J; Lor K; McDevitt-Potter L; Mohammed A; Rogers C; Tichy EM; Weng R; Lee RA
    Transplantation; 2015 Jul; 99(7):1499-505. PubMed ID: 25643140
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.